$0.8252
0.03884.93%
Perspective Therapeutics Inc (CATX) Stock Price, Quote, News & History
CATXAMEX
Perspective Therapeutics narrowed its Q3 loss to $0.27/share, but sales fell. Analysts cut price targets, sending shares down 2.4%.
You can purchase shares of Perspective Therapeutics (AMEX:CATX) through any online brokerage.
Other companies in Perspective Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Perspective Therapeutics has a consensus price target of $11.31.
The stock price for Perspective Therapeutics (AMEX: CATX) is $ last updated .
There are no upcoming dividends for Perspective Therapeutics.
Perspective Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Perspective Therapeutics.
Perspective Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the AMEX.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212...
